AstraZeneca Pharma tumbled 5.12% to Rs 6,768 after the pharmaceutical firm's net profit declined 26.62% to Rs 38.43 crore in Q2 FY25 as compared with Rs 52.37 crore posted in Q2 FY24.
AstraZeneca’s growth was driven by its portfolio of products in the oncology, biopharmaceuticals and rare disease segments ...
AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...
17h
BRITS on a budget are to face even higher prices at discount shops such as Aldi and Lidl because of the Chancellor’s tax raid ...
Hosted on MSN18h
AstraZeneca plans major $3.5bn expansion drive in the USUK-based biopharmaceutical company AstraZeneca has announced a $3.5bn investment to expand its research and manufacturing ...
Shares of AstraZeneca PLC AZN rallied 1.54% to £101.44 Wednesday, on what proved to be an all-around favorable trading ...
An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
AstraZeneca said it is doubling down on its investment in its U.S. business. Meanwhile, General Catalyst has agreed to ...
The personal luxury goods market looks set to face its first slowdown since the Global Financial Crisis, excluding the Covid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback